Literature DB >> 15806468

Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study.

Rachel L Perlman1, Fredric O Finkelstein, Lei Liu, Erik Roys, Margaret Kiser, George Eisele, Sally Burrows-Hudson, Joseph M Messana, Nathan Levin, Sanjay Rajagopalan, Friedrich K Port, Robert A Wolfe, Rajiv Saran.   

Abstract

BACKGROUND: Health-related quality of life (QOL) is an important measure of how disease affects patients' lives. Dialysis patients have decreased QOL relative to healthy controls. Little is known about QOL in patients with chronic kidney disease (CKD) before renal replacement therapy.
METHODS: The Medical Outcomes Study Short Form-36 (SF-36), a standard QOL instrument, was used to evaluate 634 patients (mean glomerular filtration rate [GFR], 23.6 +/- 9.6 mL/min/1.73 m2 [0.39 +/- 0.16 mL/s/1.73 m2]) enrolled in a 4-center, prospective, observational study of CKD. SF-36 scores in these patients were compared with those in a prevalent cohort of hemodialysis (HD) patients and healthy controls (both from historical data). QOL data also were analyzed for correlations with GFR and albumin and hemoglobin levels in multivariable analyses.
RESULTS: Patients with CKD had higher SF-36 scores than a large cohort of HD patients (P < 0.0001 for 8 scales and 2 summary scales), but lower scores than those reported for the US adult population (P < 0.0001 for 7 of 8 scales and 1 of 2 summary scales). Patients with CKD stage 4 had lower QOL scores than patients with CKD stage 5, although differences were not significant. Hemoglobin level was associated positively with higher mental and physical QOL scores (P < 0.05) in all individual and component scales except Pain.
CONCLUSION: SF-36 scores were higher in this CKD cohort compared with HD patients, but lower than in healthy controls. GFR was not significantly associated with QOL. Hemoglobin level predicted both physical and mental domains of the SF-36. Longitudinal studies are needed to define at-risk periods for decreases in QOL during progression of CKD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806468     DOI: 10.1053/j.ajkd.2004.12.021

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  125 in total

1.  Optimizing anemia management through medication reconciliation: applying the 2010 joint commission patient safety goal requirements.

Authors:  Shilpa Amara; Indu Lew; Robert T Adamson
Journal:  P T       Date:  2010-03

Review 2.  Symptom Management of the Patient with CKD: The Role of Dialysis.

Authors:  Valerie Jorge Cabrera; Joni Hansson; Alan S Kliger; Fredric O Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 8.237

3.  Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.

Authors:  Stephen Seliger; Kathleen M Fox; Shravanthi R Gandra; Brian Bradbury; Van Doren Hsu; Loreen Walker; Chiun-Fang Chiou; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 8.237

4.  Risk factors associated with disease progression and mortality in chronic kidney disease of uncertain etiology: a cohort study in Medawachchiya, Sri Lanka.

Authors:  Lalantha Senevirathna; Tilak Abeysekera; Shanika Nanayakkara; Rohana Chandrajith; Neelakanthi Ratnatunga; Kouji H Harada; Toshiaki Hitomi; Toshiyuki Komiya; Eri Muso; Akio Koizumi
Journal:  Environ Health Prev Med       Date:  2011-09-01       Impact factor: 3.674

5.  [Variables associated with a good quality of life in patients with chronic renal disease secondary to diabetic nephropathy].

Authors:  Eric Oropeza-Guzmán; Adriana Lorena Santana-Cano; Mario Alberto García-Cárdenas; Mónica Araceli Sandoval-Magaña
Journal:  Aten Primaria       Date:  2011-04-14       Impact factor: 1.137

6.  Gender and Racial Differences in Stress, Coping, and Health-Related Quality of Life in Chronic Kidney Disease.

Authors:  Leigh A Gemmell; Lauren Terhorst; Manisha Jhamb; Mark Unruh; Larissa Myaskovsky; Lauren Kester; Jennifer L Steel
Journal:  J Pain Symptom Manage       Date:  2016-09-30       Impact factor: 3.612

7.  The Use of Curcumin for the Treatment of Renal Disorders: A Systematic Review of Randomized Controlled Trials.

Authors:  Mohammad Bagherniya; Davood Soleimani; Mohammad Hossein Rouhani; Gholamreza Askari; Thozhukat Sathyapalan; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.

Authors:  Sharon M Moe; Akber Saifullah; Robert E LaClair; Sohail A Usman; Zhangsheng Yu
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

9.  Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease.

Authors:  Luiz Carlos Cichota; Rafael Noal Moresco; Marta Maria Medeiros Frescura Duarte; José Edson Paz da Silva
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

10.  Health-related quality of life and hemoglobin levels in chronic kidney disease patients.

Authors:  Fredric O Finkelstein; Kenneth Story; Catherine Firanek; David Mendelssohn; Paul Barre; Tomoko Takano; Steven Soroka; Salim Mujais
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.